A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

NCT06007690 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Melanoma
Indeterminate Lesions
Uveal Melanoma
Ocular Melanoma

Interventions

DRUG: Bel-sar
DEVICE: Suprachoroidal Microinjector
DEVICE: Infrared Laser
DEVICE: Sham Infrared Laser
DEVICE: Sham Microinjector

Sponsor

Aura Biosciences